Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Ironwood Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Ironwood Pharmaceuticals shares (IRWD) are listed on the NASDAQ and all prices are listed in US Dollars. Ironwood Pharmaceuticals employs 232 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $11.14 |
|---|---|
| 52-week range | $8.78 - $14.27 |
| 50-day moving average | $11.53 |
| 200-day moving average | $12.20 |
| Wall St. target price | $14.00 |
| PE ratio | 3.3903 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $3.25 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.14 from 2022-01-25
| 1 week (2022-01-19) | -0.45% |
|---|---|
| 1 month (2021-12-23) | -6.15% |
| 3 months (2021-10-26) | -12.49% |
| 6 months (2021-07-26) | -14.77% |
| 1 year (2021-01-26) | 9.32% |
|---|---|
| 2 years (2020-01-24) | -9.94% |
| 3 years (2019-01-25) | 12.8423 |
| 5 years (2017-01-26) | 13.9416 |
Valuing Ironwood Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ironwood Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ironwood Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Ironwood Pharmaceuticals shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ironwood Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $241.9 million.
The EBITDA is a measure of a Ironwood Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $413.3 million |
|---|---|
| Operating margin TTM | 58.45% |
| Gross profit TTM | $298.3 million |
| Return on assets TTM | 19.21% |
| Return on equity TTM | 18.1% |
| Profit margin | 128.3% |
| Book value | $3.55 |
| Market capitalisation | $1.8 billion |
TTM: trailing 12 months
We're not expecting Ironwood Pharmaceuticals to pay a dividend over the next 12 months.
Ironwood Pharmaceuticals's shares were split on a 1194:1000 basis on 1 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1194 shares. This wouldn't directly have changed the overall worth of your Ironwood Pharmaceuticals shares – just the quantity. However, indirectly, the new 16.2% lower share price could have impacted the market appetite for Ironwood Pharmaceuticals shares which in turn could have impacted Ironwood Pharmaceuticals's share price.
Over the last 12 months, Ironwood Pharmaceuticals's shares have ranged in value from as little as $8.7819 up to $14.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ironwood Pharmaceuticals's is 1.2078. This would suggest that Ironwood Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Ironwood Pharmaceuticals, Inc. , a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc. , AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.